Ensysce Biosciences (ENSCW) Net Margin (2020 - 2025)
Ensysce Biosciences (ENSCW) reported Net Margin of 756.26% for Q3 2025, down 77561.0% year-over-year from N/an in Q3 2024, and down 498.35% quarter-over-quarter from 126.39% in Q2 2025.
Ensysce Biosciences (ENSCW) Net Margin (2020 - 2025) Analysis & Trends
Ensysce Biosciences (ENSCW) has 6 years of Net Margin data on file, last reported at 756.26% in Q3 2025.
- Net Margin for Q3 2025 came in at 756.26%, down 77561.0% year-over-year; the trailing twelve-month figure through Sep 2025 was 244.49% (down 6520.0% YoY), and the FY2024 annual result was 153.3%, up 32309.0% from the prior year.
- Net Margin declined to 756.26% in Q3 2025 per ENSCW's latest filing, from 126.39% in the prior quarter.
- Over five years, Net Margin peaked at 19.36% in Q3 2024 and troughed at 3855.62% in Q2 2022.
- A 5-year average of 849.65% and a median of 455.88% in 2023 frame the typical range for Net Margin.
- The sharpest annual moves came in 2022 and 2023: Net Margin plunged 364515 bps in 2022, then jumped 339974 bps in 2023.
- A 5-year view of Net Margin shows it stood at 662.88% in 2021, then jumped by 42 bps to 385.21% in 2022, then slumped by 77 bps to 680.4% in 2023, then soared by 60 bps to 273.42% in 2024, then slumped by 177 bps to 756.26% in 2025.
- Business Quant data shows ENSCW's Net Margin at 756.26% in Q3 2025, 126.39% in Q2 2025, and 147.42% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.82% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 34.53% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Ensysce Biosciences | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -756.26% |
| Jun 30, 2025 | -126.39% |
| Mar 31, 2025 | -147.42% |
| Dec 31, 2024 | -273.42% |
| Sep 30, 2024 | 19.36% |
| Jun 30, 2024 | -1,082.41% |
| Mar 31, 2024 | -1,019.48% |
| Dec 31, 2023 | -680.40% |
| Sep 30, 2023 | -617.75% |
| Jun 30, 2023 | -455.88% |
| Mar 31, 2023 | -278.13% |
| Dec 31, 2022 | -385.21% |
| Sep 30, 2022 | -3,543.07% |
| Jun 30, 2022 | -3,855.62% |
| Mar 31, 2022 | -276.35% |
| Dec 31, 2021 | -662.88% |
| Sep 30, 2021 | -1,429.32% |
| Jun 30, 2021 | -210.46% |
| Mar 31, 2021 | -362.26% |
| Dec 31, 2020 | 51.38% |